Tech

October 12, 2012

NASA signs agreement to develop nasal spray for motion sickness

NASA’s Johnson Space Center in Houston and Epiomed Therapeutics Inc. of Irvine, Calif., have signed an agreement to develop and commercialize a NASA-crafted, fast-acting nasal spray to fight motion sickness.

Under the Space Act Agreement, Epiomed will formulate the drug, called intranasal scopolamine, or INSCOP. Astronauts often experience motion sickness in space. As a result, NASA has conducted extensive research into the causes and treatments for the condition. Scopolamine is effective and can be administered as a tablet or injected. With

precise dosage, the NASA spray formulation has been shown to work faster and more reliably than the oral form.

“NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas,” said Lakshmi Putcha, developer of the innovative treatment strategy at Johnson.

A gel formulation of INSCOP was developed and tested under a Space Act Agreement between Johnson and the Naval Aerospace Medical Research Laboratory in Pensacola, Fla. Results from that trial were published in the journal Aviation, Space and Environmental Medicine in April 2010 that suggest INSCOP is a fast-acting and reliable way to prevent and treat motion sickness.

The U.S. Navy is working on an agreement with Epiomed to test the nasal spray. NASA and Epiomed will collaborate on clinical trials related to the Federal Drug Administration requirements. NASA is transferring sponsorship of future clinical trials and FDA approvals to Epiomed, which will supply the product for use by NASA and others.

 




All of this week's top headlines to your email every Friday.


 
 

 

Headlines September 19, 2014

News: McKeon on broader military authorization: Anything can ‘fail or pass’ - Rep. Howard “Buck” McKeon, R-Calif., chairman of the House Armed Services Committee, said if Congress returns after the midterm elections to weigh a broader military authorization for the battle against Islamic State, it might not pass. Defense contractor gets 7 years for giving secrets...
 
 

News Briefs September 19, 2014

U.S. military deaths in Afghanistan at 2,203 As of Sept. 16, 2014, at least 2,203 members of the U.S. military had died in Afghanistan as a result of the U.S.-led invasion of Afghanistan in late 2001, according to an Associated Press count. At least 1,823 military service members have died in Afghanistan as a result...
 
 

Pratt & Whitney, U.S. Air Force complete qualification for F135 engine testing

Pratt & Whitney, a United Technologies Corp. , together with its U.S. Air Force partner at the F135 Heavy Maintenance Center at Tinker Air Force Base, Okla., celebrated another significant milestone qualification for F135 engine testing at the Oklahoma City Air Logistics Complex. OC-ALC which in addition to engine testing is also qualified to perform...
 

 
Navy photograph

Triton has first cross-country flight from Palmdale

Northrop Grumman photograph The MQ-4C Triton Unmanned Aircraft System takes off from Northrop Grummanís Palmdale, Calif., facility Sept. 17 for its first cross-country flight to Naval Air Station Patuxent, River, Md. PALMDALE,...
 
 
Air Force photograph by Michael J. Pausic

Future of NATO: Adapting to a new security environment

Air Force photograph by Michael J. Pausic Gen. Phillip Breedlove informs the assembled crowd about the results of the recent NATO Summit and the areas of instability that affect Europe that have regional implications. Seated in...
 
 
Air Force photograph by Scott M. Ash

AFRL commander describes Air Force’s technology vision

Air Force photograph by Scott M. Ash Maj. Gen. Thomas Masiello takes a question from an audience member after discussing Air Force Research Laboratory breakthrough technologies during the 2014 Air Force Association’s Air ...
 




0 Comments


Be the first to comment!


Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>